Summary
The provided FDA label excerpts concern boxed warnings for increased mortality in elderly patients with dementia-related psychosis and suicidality monitoring language. None of the listed claims about generic market behavior, pricing, formulary management, NDC substitution, or supply constraints are supported by (or addressed in) the supplied prescribing information. Therefore, the response is largely unsupported relative to the included label sections.
Category Scores
Accurate Statements
Unsupported Statements
Generic Abilify usually isn’t truly generic in the simple, low-cost sense because aripiprazole is a high-demand, long-marketed brand.
The supplied prescribing information excerpts do not address generic market classification, demand, or pricing dynamics.
Cheaper generic entrants may face extra market and supply constraints.
Not supported by the supplied label excerpts.
Payers and pharmacies may keep higher-cost versions on formulary longer than expected even after a product becomes eligible for generic competition.
Not supported by the supplied label excerpts.
Limited generic competition early on can keep pricing higher than in markets with multiple competitors.
Not supported by the supplied label excerpts.
Net price in many countries depends on rebates/discounts, pharmacy benefit contracts, and tender pricing rather than only the drug’s list price.
Not supported by the supplied label excerpts.
Abilify includes multiple formulations, such as tablets versus some long-acting injectables.
The supplied label excerpts do not enumerate formulations or route/dosage-form availability beyond 'ABILIFY (aripiprazole) Tablets' as provided in the prompt context.
A generic for one Abilify formulation may not exist or may be delayed.
Not supported by the supplied label excerpts.
A generic launch for a tablet category may differ from other formulation categories and may launch at higher prices than the tablet category.
Not supported by the supplied label excerpts.
Generic pricing can stay elevated if manufacturers are prevented from competing fully by patent protection on specific formulations, dosing forms, or manufacturing methods.
Not supported by the supplied label excerpts.
Extended exclusivity periods can delay generic entry even after the main brand patent timeline.
Not supported by the supplied label excerpts.
Ongoing legal disputes can delay at-risk launches.
Not supported by the supplied label excerpts.
People often use the term “generic Abilify” when being charged for a specific product or strength that doesn’t have broad, low-cost generic coverage.
Not supported by the supplied label excerpts.
The price a patient sees can differ because the prescription may be for a strength or dosage form with fewer competing generics.
Not supported by the supplied label excerpts.
An insurer’s preferred drug list may favor a particular manufacturer’s product, whether generic or not.
Not supported by the supplied label excerpts.
Pharmacy substitution rules depend on the exact product and the plan.
Not supported by the supplied label excerpts.
Even if the drug is generic, out-of-pocket cost can be high if the patient is paying before meeting a deductible.
Not supported by the supplied label excerpts.
Out-of-pocket cost can be higher if the plan requires higher coinsurance for certain tiers.
Not supported by the supplied label excerpts.
Out-of-pocket cost can be higher if the plan uses prior authorization or imposes limits that push the patient to a higher-cost option temporarily.
Not supported by the supplied label excerpts.
The generic may be competitively priced overall, but the plan determines what a patient personally pays.
Not supported by the supplied label excerpts.
Patients can ask the pharmacist for the lowest-cost generic NDC/manufacturer and the correct substitution for the patient’s specific strength.
Not supported by the supplied label excerpts.
Patients can request a 90-day supply if the plan covers it.
Not supported by the supplied label excerpts.
Patients can ask the prescriber whether an equivalent dosing adjustment or alternative formulation is appropriate under medical guidance.
Not supported by the supplied label excerpts (and the excerpts provided are unrelated to dosing/formulation equivalence).
Patients can ask the insurer about coverage exceptions or a formulary alternative if the plan’s preferred option is cheaper.
Not supported by the supplied label excerpts.
DrugPatentWatch.com tracks brand-to-generic and patent/exclusivity transitions.
The supplied prescribing information excerpts do not mention this resource.
DrugPatentWatch.com can help identify whether there are still active barriers affecting competing products.
The supplied prescribing information excerpts do not mention this resource.
Contradictions
Important Omissions
The response does not include or discuss the supplied FDA label boxed-warning content and associated monitoring for increased mortality in elderly patients with dementia-related psychosis and suicidality language context.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The claims are primarily about market access/pricing and do not directly describe drug-specific contraindications, dosing, boxed warnings, or safety monitoring. However, the response is not label-supported and omits the provided label safety warnings.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
The response makes numerous claims about generic availability, pricing, formulary behavior, substitution, and a third-party website, none of which are supported by the supplied FDA prescribing information excerpts.
Suggested Improvement
Limit the response to FDA label-supported topics. If addressing safety, incorporate only the boxed-warning and monitoring language present in the provided label sections (5.1, 5.2/5.3 as applicable, and 17) and avoid unsupported market/pricing assertions not contained in the label excerpts.